Publications by authors named "Krisztina Budai"
Introduction: Therapeutic treatment for advanced-stage (T-T) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.
Method: Neoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT or higher nodal positive cN+ disease (Group 2).
Article Synopsis
- The study discusses the shift in treatment for advanced gastro-oesophageal junction cancer, using neoadjuvant chemotherapy followed by surgery, focusing on two different chemotherapy regimens: ECF/ECX (Group I) and FLOT (Group II).
- The research involved analyzing surgical outcomes, tumor regression, and side effects from these two chemotherapy protocols in patients with T2-T4 tumors over a specific time period.
- Results indicated that the FLOT protocol led to a significantly higher number of complete tumor regressions compared to the older ECF/ECX treatment, though no major differences in surgical safety and side effects were observed between the two groups.